4 Health Care Stocks With Whale Alerts In Today's Session

Breckenridge Pharmaceutical Rolls Out Generic Equivalent Of Pfizer's Xeljanz

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, announced the launch of Tofacitinib Tablets, the generic

Chai Discovery Inks License Agreement With Pfizer To Deploy Its AI Platform As Part Of Drug Discovery Engine

Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.The agreement will enable Pfizer to deploy Chai's AI platform

Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields

In turbulent markets, investors turn to dividend-yielding stocks. Here are analyst ratings for high-yielding energy stocks.

Pfizer Announces Unprecedented 7-Yr Follow-Up Results From Phase 3 CROWN Trial Evaluating LORBRENA Vs XALKORI In People With ALK-Positive Advanced Or Metastatic NSCLC

Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENAUpdated follow-up analysis solidifies LORBRENA as a preferred

Pfizer and Innovent Join Forces to Develop 12 New Cancer Treatments Worldwide

Pfizer Inc. (NYSE:PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

U.S. FDA Advisers Vote In Favor Of Recommending Covid Vaccines Target JN.1 Lineage XFG Variant For 2026-27 Campaign

https://www.fda.gov/media/186593/download

Pfizer Expands Pneumococcal Vaccine Push With New Programs

Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20.

Pfizer Advances Next-Generation Pediatric Pneumococcal Vaccine After Phase 2 Data Showed Significantly Higher Serotype 3 Immune Response

Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric